{"id":2184,"date":"2026-06-09T04:00:00","date_gmt":"2026-06-09T07:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2184"},"modified":"2026-06-09T04:00:00","modified_gmt":"2026-06-09T07:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-vesical-cistectomia-radical-neobexiga-ileal-indiana-pouch-brachy","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-vesical-cistectomia-radical-neobexiga-ileal-indiana-pouch-brachy\/","title":{"rendered":"PGRSS vesical: cistectomia, neobexiga, Indiana"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica vesical que reduzem PGRSS a descarte de sonda Foley e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica vesical<\/strong> + cistectomia radical com deriva\u00e7\u00e3o urin\u00e1ria<\/strong> + neobexiga ortot\u00f3pica ileal Hautmann\/Studer<\/strong> + Indiana pouch heterot\u00f3pica continente<\/strong> + brachy intersticial vesical Iridium-192<\/strong> + TURBT ressec\u00e7\u00e3o transuretral bexiga<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (carcinoma urotelial vesical + adenoCa + carcinoma escamoso) + Grupo A4 (linfa p\u00e9lvica + obturador + il\u00edaca + para-a\u00f3rtica) + Grupo C (Iridium-192 brachy + LDR\/HDR) + Grupo E (perfuro TURBT + ressectosc\u00f3pio) + BCG (Bacilo Calmette-Gu\u00e9rin imunoterapia intravesical Lista C5). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para sonda urin\u00e1ria<\/strong> + ignoram especificidades oncol\u00f3gicas + deriva\u00e7\u00e3o urin\u00e1ria<\/strong> + subdimensionam fluxo radioativo brachy<\/strong> + perdem rastreabilidade tumor<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS vesical opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (carcinoma urotelial CIS + Ta + T1 + T2 invasivo + T3-T4), A4 (LN ND linfadenectomia p\u00e9lvica estendida + obturador + il\u00edaca interna\/externa\/comum + para-a\u00f3rtica), C (Iridium-192 brachy intersticial + after-loading + dosimetria), E (TURBT ressectosc\u00f3pio Storz\/Wolf 24-26Fr + al\u00e7a monopolar\/bipolar), BCG (Bacilo Calmette-Gu\u00e9rin TICE\/Connaught\/Tokyo intravesical Lista C5).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica vesical, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos vesicais<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS vesical tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 carcinoma urotelial<\/td>\n5-15 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCIS+Ta+T1+T2+T3-T4<\/td>\n<\/tr>\n
A4 LN p\u00e9lvica estendida<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nObturador+il\u00edaca+para-a\u00f3rtica<\/td>\n<\/tr>\n
C Iridium-192 brachy<\/td>\n0,5-1,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nLDR\/HDR+CNEN<\/td>\n<\/tr>\n
E TURBT ressectosc\u00f3pio<\/td>\n1,5-4 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nAl\u00e7a mono\/bipolar<\/td>\n<\/tr>\n
BCG intravesical<\/td>\n0,8-2,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nLista C5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,8-35 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica vesical m\u00e9dia porte.<\/p>\n

A1 carcinoma urotelial + cistectomia radical: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS vesical \u00e9 A1. Padr\u00e3o setorial inclui (a) cistectomia radical<\/strong> com bexiga + pr\u00f3stata + ves\u00edculas seminais (homem) + bexiga + \u00fatero + anexos + parede vaginal anterior (mulher) + ureteres distais; (b) deriva\u00e7\u00e3o urin\u00e1ria<\/strong> com neobexiga ortot\u00f3pica ileal<\/strong> Hautmann W-shape\/Studer U-shape\/Camey II + 50-60cm \u00edleo terminal + reservat\u00f3rio baixa press\u00e3o + anastomose uretral; (c) Indiana pouch heterot\u00f3pica continente<\/strong> com c\u00f3lon ascendente + \u00edleo terminal + v\u00e1lvula ileocecal continente + estoma umbilical autocateterismo CIC; (d) conduto ileal Bricker incontinente<\/strong> com 15-20cm \u00edleo + estoma cut\u00e2neo + bolsa coletora; (e) tipo histol\u00f3gico<\/strong> carcinoma urotelial 90% + escamoso 5% + adeno 2% + pequenas c\u00e9lulas 2% + sarcomatoide 1% + CID C67.<\/p>\n

Cl\u00ednica com A1 cir oncol\u00f3gica vesical madura garante margem R0<\/strong> + previne recidiva p\u00e9lvica<\/strong> + otimiza deriva\u00e7\u00e3o urin\u00e1ria qualidade vida<\/strong>. Como discutimos no post sobre PGRSS oncologia<\/a>, A1 \u00e9 a base.<\/p>\n

A4 linfadenectomia p\u00e9lvica estendida + BCG intravesical: o est\u00e1gio metast\u00e1tico+imuno<\/h2>\n

A segunda camada \u00e9 A4 + BCG. Padr\u00e3o setorial inclui (a) linfadenectomia p\u00e9lvica estendida<\/strong> ePLND com obturador + il\u00edaca interna + externa + comum + presacral + para-a\u00f3rtica at\u00e9 bifurca\u00e7\u00e3o a\u00f3rtica + 25-40 LN dissecados padr\u00e3o ouro; (b) bi\u00f3psia LN sentinela vesical<\/strong> com Tc-99m + ICG verde indocianina + DSL Dynamic Sentinel + experimental; (c) BCG intravesical<\/strong> com TICE + Connaught + Tokyo cepas + 81 mg\/instila\u00e7\u00e3o semanal \u00d7 6 + manuten\u00e7\u00e3o 3 anos SWOG protocol Lista C5; (d) falha BCG<\/strong> com BCG-failure + BCG-refractory + BCG-relapsing + alternativa pembrolizumab Keytruda Merck FDA-approved 2020 + nadofaragene firadenovec Adstiladrin Ferring + N-803 Anktiva ImmunityBio; (e) descarte BCG<\/strong> com saco amarelo + identifica\u00e7\u00e3o Lista C5 imuno + lacre + rastreabilidade + descarte espec\u00edfico BCG biol\u00f3gico micobacteriano.<\/p>\n

Cl\u00ednica com A4+BCG madura detecta micromet\u00e1stase ePLND<\/strong> + previne progress\u00e3o<\/strong> + gerencia BCG falha<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

C Iridium-192 brachy + TURBT: o est\u00e1gio radioativo+endosc\u00f3pico<\/h2>\n

A terceira camada \u00e9 C brachy + E TURBT. Padr\u00e3o setorial inclui (a) braquiterapia intersticial vesical<\/strong> com Iridium-192 LDR low dose rate + HDR high dose rate + after-loading remote + agulhas paralelas + template vesical + dosimetria 3D ICRU-58; (b) brachy boost<\/strong> com 60-65 Gy boost intersticial + EBRT 45 Gy WBRT p\u00e9lvica + bexiga D2cc <80 Gy + reto D2cc <70 Gy; (c) rejeito radioativo classe 3<\/strong> com decaimento Ir-192 t\u00bd=74 dias + 10 meias-vidas + decaimento dep\u00f3sito monitorado + rejeito final IPEN\/CNEN-NN-3.05; (d) TURBT ressec\u00e7\u00e3o transuretral<\/strong> com ressectosc\u00f3pio Storz Karl Karl Storz 24-26Fr + Wolf Polaris + al\u00e7a monopolar tradicional + al\u00e7a bipolar PlasmaButton\/PlasmaKinetic Olympus; (e) descarte TURBT<\/strong> com fragmentos vesicais ressecados + soro fisiol\u00f3gico irriga\u00e7\u00e3o + perfuro al\u00e7a + RSS Grupo A1 fragmento + Grupo E perfuro + lacre rastre\u00e1vel.<\/p>\n

Cl\u00ednica com C+E madura escala radioterapia conservadora<\/strong> + preserva bexiga fun\u00e7\u00e3o<\/strong> + garante CNEN compliance<\/strong>. Conex\u00e3o com Iridium-192 brachy<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade vesical<\/h2>\n

Cl\u00ednica vesical s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+C+E+BCG.<\/p>\n

Cl\u00ednica vesical A1 + A4 + BCG.<\/strong> 3 fluxos. Custo mensal R$ 22.000-58.000<\/strong>, captura cirurgia + linfa + imuno.<\/p>\n

Cl\u00ednica vesical 5 fluxos completos.<\/strong> A1+A4+C+E+BCG + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 38.000-92.000<\/strong>, efic\u00e1cia 95%, ROI 900-2.700% via captura completa vesical.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica vesical<\/h2>\n

O primeiro \u00e9 a subdimensionamento BCG Lista C5<\/strong>. Sem segrega\u00e7\u00e3o imuno + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional.<\/p>\n

O segundo \u00e9 a mistura A1 carcinoma + A4 LN p\u00e9lvica<\/strong>. Confunde rastreabilidade tumor + impossibilita ePLND padronizado 25-40 LN.<\/p>\n

O terceiro \u00e9 a falta de protocolo deriva\u00e7\u00e3o urin\u00e1ria + neobexiga<\/strong>. Sem rastreabilidade Hautmann\/Studer\/Indiana\/Bricker = zero auditoria qualidade vida + risco reopera\u00e7\u00e3o.<\/p>\n

A regula\u00e7\u00e3o de PGRSS vesical no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer Bexiga<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS vesical 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 cistectomia radical+deriva\u00e7\u00e3o Hautmann W+Studer U+Camey II+Indiana pouch+Bricker, A4 ePLND obturador+il\u00edaca interna\/externa\/comum+para-a\u00f3rtica 25-40 LN+sentinela DSL, C Iridium-192 LDR\/HDR brachy+CNEN-NN-3.05+IPEN, E TURBT Storz 24-26Fr+Wolf+al\u00e7a mono\/bipolar+PlasmaButton, BCG TICE+Connaught+Tokyo+pembrolizumab Keytruda+nadofaragene Adstiladrin Lista C5.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS oncologia vesical: cistectomia + neobexiga + Indiana + brachy. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2183,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,3021,3022,3020],"class_list":["post-2184","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-cistectomia","tag-neobexiga","tag-vesical"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2184"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2184\/revisions"}],"predecessor-version":[{"id":4316,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2184\/revisions\/4316"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2183"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}